Loading clinical trials...

Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019) | Clinical Trials | Clareo Health

RECRUITINGPHASE3

Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)

Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section: a Single-arm, Multi-center, Phase III Trial

NCT06031181•Fudan University

View on ClinicalTrials.gov

Summary

This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1019. The goal of this clinical trial is to confirm the therapeutic effect of sublobar resection for AIS/MIA diagnosed by intraoperative frozen section.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients who sign the informed consent form and are willing to complete the study according to the plan;
•2. Aged from 18 to 80 years old;
•3. ECOG equals 0 or 1;
•4. Not receiving lung cancer surgery before;
•5. Resectable peripheral cT1N0M0 tumors;
•6. Single lung nodules with ground-glass dominant or pure ground-glass on CT, or multiple lung nodules with the major lesion being the aforementioned nodules;
•7. Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section
•8. Not receiving chemotherapy or radiotherapy before.

Exclusion Criteria

•1. Not cT1N0M0;
•2. Cannot be completely resected by sublobar resection;
•3. Invasive lung adenocarcinoma or not lung adenocarcinoma diagnosed cytologically or pathologically;
•4. Receiving lung cancer surgery before;
•5. Receiving radiotherapy or chemotherapy.

Locations (1)

Fudan University Cancer Center

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

March 31, 2023

Primary Completion Date

January 1, 2026

Completion Date

December 31, 2030

Last Updated

December 13, 2023

Enrollment

390

ESTIMATED participants

Conditions

Lung AdenocarcinomaFrozen SectionSublobar Resection

Interventions

Sublobar Resection

PROCEDURE

Contacts

Chaoqiang Deng

CONTACT

+86-13122677592 fdudengcq@163.com

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

NCT05198830

Lung AdenocarcinomaLung Large Cell Carcinoma+2 more

View study

RECRUITINGNA

Engagement of Veterans With Lung Cancer

NCT07219251

Lung Cancer (NSCLC)Lung Adenocarcinoma+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 13, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Engagement of Veterans With Lung Cancer

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers

Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)